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g-glutamyl transpeptidase to platelet ratio with
liver fibrosis in chronic hepatitis CDear Editor,
We read the report of Lemoine et al [1] with great interest.
They identified the g-glutamyl transpeptidase to platelet
ratio (GPR) as a surrogate marker of advanced liver disease
in African patients with hepatitis B virus infection. We
validated the utility of this ratio in a study of 892 biopsies
from patients with confirmed chronic hepatitis C (CHC)
infection who were prescribed pegylated interferon/P<0.001
P<
Non-DM
Figure 1. Association of g-glutamyl transpeptidase to platelet r
betes mellitus.
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excluded from this cohort. Advanced liver disease (fibrosis
3e4) and diabetes were found in 29.9% and 13.8% of the
CHC cohort, respectively. The mean GPR was 0.74  0.76.
The area under the receiving operator characteristic curve
of the GPR in predicting advanced liver fibrosis was 0.69
[cut-off: 0.75, 95% confidence interval (CI): 0.65e0.73,
p < 0.001]. Linear regression analysis revealed thatP<0.001P=0.87
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atio with liver disease severity in patients with or without dia-
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Letter to the Editor 335independent factors correlated with GPR, including
advanced fibrosis (Metavir fibrosis score 3e4) (b: 0.231; 95%
CI: 0.288e0.482; p < 0.001), diabetes (b: 0.194; 95% CI:
0.307e0.568; p < 0.001), male gender (b: 0.193; 95% CI:
0.209e0.385; p < 0.001), elevated aspartate aminotrans-
ferase (b: 0.321; 95% CI: 0.003e0.005; p < 0.001) and
steatosis (b: 0.064; 95% CI: 0.011e0.187; p Z 0.028).
Accordingly, several confounders might interfere with the
interpretation of the index. As diabetes is not uncommon
among CHC patients [2], careful interpretation of GPR is
required. Patients with diabetes had a significantly higher
GPR compared with nondiabetic patients (1.23  1.09 vs
0.66  0.67, p < 0.001). Compared with patients with mild
liver disease, the GPR was significantly higher in those with
advanced liver disease with (1.55  1.26 vs 0.96  0.85,
p < 0.001) or without diabetes (0.96  0.92 vs 0.55  0.49,
p < 0.001). However, there was no difference in the GPRs
between diabetic patients with mild fibrosis and nondia-
betic patients with advanced fibrosis (pZ 0.87) (Figure 1).
It is noteworthy that elevated r-glutamyl transpeptidase
has been associated with b-cell dysfunction [3] and Type 2
diabetes [4] irrespective of liver disease severity. Further-
more, we have recently demonstrated that diabetes mel-
litus interacts with host genetics in contributing to hepatitis
C virus (HCV)-related liver fibrosis [5]. Taken together,
evaluation of the association of GPR with liver fibrosis in
CHC patients should take diabetes status into consider-
ation. Unlike patients with hepatitis B virus infection, there
is a strong link between HCV and diabetes. This clinical
scenario is frequently neglected. It is estimated that only
one-third of CHC patients are normoglycemic [2]. In view of
the high prevalence of diabetes in CHC patients and in
western countries, the application of this tool in the
context of CHC infection should be interpreted cautiously.
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